Evidence map›Paper›PMID 34329530›Full record

ArticleChemMedChem2021

Investigation of the Effects and Mechanisms of Anticancer Action of a Ru(II)-Arene Iminophosphorane Compound in Triple Negative Breast Cancer Cells.

Nazia Nayeem, Arefa Yeasmin, Samantha N Cobos, Ali Younes, Karen Hubbard, Maria Contel

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Nazia NayeemDepartment of Chemistry and Brooklyn College Cancer Center, Brooklyn College, The City University of New York, Brooklyn, NY, 11210, USA.ORCID 0000-0001-6733-6965
Arefa YeasminDepartment of Chemistry and Brooklyn College Cancer Center, Brooklyn College, The City University of New York, Brooklyn, NY, 11210, USA.
Samantha N CobosDepartment of Chemistry and Brooklyn College Cancer Center, Brooklyn College, The City University of New York, Brooklyn, NY, 11210, USA.
Ali YounesDepartment of Chemistry, Hunter College, The City University of New York, 695 Park Avenue, New York, NY, 10065, USA.
Karen HubbardBiology, Chemistry and Biochemistry PhD Programs, The Graduate Center, The City University of New York, New York, NY, 10016, USA.ORCID 0000-0003-4723-9126
Maria ContelDepartment of Chemistry and Brooklyn College Cancer Center, Brooklyn College, The City University of New York, Brooklyn, NY, 11210, USA.ORCID 0000-0002-9825-4441
The Graduate Center, CUNY · USCity University of New York · US

Funding

Training and Career Development CoreU54CA132378 · NCI · CITY COLLEGE OF NEW YORK · PI Tim Alan Ahles, ADRIANA ESPINOSA · 2008 to 2026
$28.9M
Training and Career Development and Education CoreU54CA137788 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Daniel Alan Heller · 2008 to 2026
$28.1M
Biodegradable nanocarriers and antibodies as targeting delivery vehicles for cancer metallodrugsSC1GM127278 · NIGMS · BROOKLYN COLLEGE · PI CONTEL, MARIA · 2018 to 2021
$1.6M
NCI NIH HHS U54 CA132378NCI NIH HHS U54 CA137788NIGMS NIH HHS SC1 GM127278
6 · The paper itself

Abstract

Triple negative breast cancer (TNBC) is one of the breast cancers with poorer prognosis and survival rates. TNBC has a disproportionally high incidence and mortality in women of African descent. We report on the evaluation of Ru-IM (1), a water-soluble organometallic ruthenium compound, in TNBC cell lines derived from patients of European (MDA-MB-231) and African (HCC-1806) ancestry (including IC

Indexed as

Antineoplastic AgentsCell CycleCell DeathCell Line, TumorCell MovementCell ProliferationCoordination ComplexesDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansIminesMolecular StructurePhosphoranesRubidiumStructure-Activity RelationshipTriple Negative Breast NeoplasmsAntineoplastic AgentsCoordination ComplexesIminesPhosphoranesRubidiumAntiangiogenicAntimetastaticHealth DisparitiesRutheniumTriple Negative Breast Cancer

Identifiers

PMID34329530
PMCPMC8571052
OpenAlexW3186519269

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.